Clinical Scorecard: From Molecules to Meaning

At a Glance

Key Highlights

• Molecular testing distinguishes tumors with different biological behaviors.
• p16 immunohistochemistry serves as a prognostic marker for HPV infection.
• Immune biomarkers guide the selection of immunotherapy.
• Liquid biopsy techniques like ctDNA enable non-invasive monitoring and early detection.
• Effective communication of molecular findings enhances patient trust and treatment confidence.

Guideline-Based Recommendations

Diagnosis

• Utilize molecular testing to confirm or exclude hereditary cancer syndromes.
• Employ p16 immunohistochemistry for HPV-related prognosis.

Management

• Incorporate immune biomarkers in treatment decision-making for head and neck cancers.
• Use ctDNA for real-time monitoring of treatment response.

Monitoring & Follow-up

• Implement liquid biopsy approaches for early detection of recurrence.

Risks

• Avoid overtreatment by accurately interpreting molecular test results.

Patient & Prescribing Data

Patients with recurrent or metastatic head and neck cancers.

Molecular pathology informs therapy selection, enhancing the likelihood of treatment response.

Clinical Best Practices

• Molecular pathologists should actively participate in multidisciplinary decision-making.
• Communicate molecular findings in clear, patient-relevant language.

References